# Long-term Efficacy of Once Daily Versus Twice Daily Aspirin in High-risk MPN Patients With Aspirin Resistance

> **NCT06740916** · PHASE3 · RECRUITING · sponsor: **Siriraj Hospital** · enrollment: 240 (estimated)

## Conditions studied

- Myeloproliferative Neoplasms (MPN)

## Interventions

- **DRUG:** 81-mg aspirin once daily
- **DRUG:** 81-mg aspirin twice daily

## Key facts

- **NCT ID:** NCT06740916
- **Lead sponsor:** Siriraj Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-12-12
- **Primary completion:** 2027-12-31
- **Final completion:** 2030-12-31
- **Target enrollment:** 240 (ESTIMATED)
- **Last updated:** 2024-12-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06740916

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06740916, "Long-term Efficacy of Once Daily Versus Twice Daily Aspirin in High-risk MPN Patients With Aspirin Resistance". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06740916. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*